Laura Ekblad
MD, PhD
positron emission tomography; Alzheimer´s Disease; Insulin resistance; cognition; memory disorders
Specialist in Geriatrics and Family Medicine. Senior researcher, Turku Alzheimer Imaging Group, Turku PET Centre.
My research focuses on early risk factors for memory disorders, especially Alzheimer´s disease. I am particularly interested in the associations between metabolic risk factors (insulin resistance, glucose intolerance, obesity) and cognitive decline.
Our lab uses multimodal neuroimaging (PET-imaging, MRI) combined with blood and CSF biomarkers and cognitive testing to explore the association between different risk factors and early cerebral changes of memory disorders.
I also run a project that examines possible cardiac side effects of anti-dementia agents in elderly memory clinic patients.
1 of 2
- Effects of Cholinesterase Inhibitor Medication on QTc Interval in Memory Clinic Patients (2025)
- Annals of Pharmacotherapy
- Enhancing dementia prediction: A 19-year validation of the CAIDE risk score with insulin resistance and APOE ε4 integration in a population-based cohort (2025)
- The Journal of Prevention of Alzheimer's Disease
- Metabolic dysfunction-associated steatotic liver disease as a predictor of cognitive performance: An 11-year population-based follow-up study (2025)
- Digestive and Liver Disease
- Neuroinflammation in Parkinson’s disease : A study with [11C]PBR28 PET and cerebrospinal fluid markers (2025)
- Parkinsonism and Related Disorders
- Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly (2024)
- Alzheimer's Research and Therapy
- Cognitively healthy APOE4/4 carriers show white matter impairment associated with serum NfL and amyloid-PET (2024)
- Neurobiology of Disease
- Midlife insulin resistance, APOE genotype, and change in late-life brain beta-amyloid accumulation : A 5-year follow-up [11C]PIB-PET study (2024)
- Neurobiology of Disease
- SV2A PET shows hippocampal synaptic loss in cognitively unimpaired APOE ε4/ε4 homozygotes (2024)
- Alzheimer's and Dementia
- APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly (2023)
- Alzheimer's Research and Therapy
- EKG-löydökset vaikeuttavat muistisairauden lääkehoitoa (2023)
- Lääkärilehti
- Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer's disease (2023)
- Neurobiology of Disease
- Impaired Early Insulin Response to Glucose Load Predicts Episodic Memory Decline: A 10-Year Population-Based Cohort Follow-Up of 45-74-Year-Old Men and Women (2023)
- Journal of Alzheimer's Disease
- Insulin resistance and body mass index are associated with TSPO PET in cognitively unimpaired elderly (2023)
- Journal of Cerebral Blood Flow and Metabolism
- ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease - Study Protocol and Baseline Characteristics (2022)
- Frontiers in Neurology
- Association of Midlife Inflammatory Markers With Cognitive Performance at 10-Year Follow-up (2022)
- Neurology
- Iäkkäiden muistisairaudet tarvitsevat erikoisosaajia (2022)
- Lääkärilehti
- Insulin Resistance and the Brain-Novel Insights Combining Metabolic Research and Neuroscience (2022)
- Metabolites
- Neuropsykologiset tehtäväsarjat Alzheimerin taudin prekliinisen vaiheen hienoisen kognitiivisen heikentymisen havaitsemisessa (2022)
- Duodecim
- Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum (2022)
- JAMA Neurology
- Association of Early β-Amyloid Accumulation and Neuroinflammation Measured With [11C]PBR28 in Elderly Individuals Without Dementia (2021)
- Neurology
UTU Research Portal